In addition to DNMT inhibitors and HDAC inhibitors, innovative epigenetic treatment targeting KATs, BETs, KMTs, KDMs, and ncRNAs are emerging and will provide novel treatment strategies in hematologic malignancies. Here, DNMT1 is linked to hematologic disorder.